SGLT2 Inhibitor Prescribing Practices in a Large Health System

Background: Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of medication that act on the renal proximal convoluted tubules to reduce the reabsorption of glucose. They were primarily used in diabetics to assist with glucose control and are now approved for the treatment of heart failure and chronic kidney disease (CKD). Once started on SGLT2 inhibitors, patients must be monitored for a decline in renal function especially if they are also put on angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and/or diuretics, as they can lead to decreases in kidney function and dehydration/hypotension. Methods: This is a retrospective cohort study of patients who were prescribed SGLT2 inhibitors in the Jefferson Health System. Data was sourced from the electronic medical record (EMR) using a customized query that returned the most recent 3 glomerular filtration rate (GFR) measurements, diagnostic codes, prescribed ACEi or ARB therapy, and prescribed diuretics. Results: Eleven thousand and eighteen adults with SGLT2 inhibitors in their medication lists were analyzed. Of these, 5956 (54.1%) patients had no GFR on record, 8744 (79.4%) were diagnosed with diabetes, 7152 (64.9%) were on concurrent ACEi/ARB therapy and 3579 (32.5%) were on diuretics. Conclusion: SGLT2 inhibitors have become the standard of care in patients with diabetes, CKD, cardiovascular disease, and heart failure. However, the proportion of patients in our study with CKD and heart failure was lower than expected, 6.9% and 1.9%, respectively. The concurrent use of ACEi/ARB medications and diuretics can be safe provided there is adequate monitoring of the fluid status and renal function. A substantial proportion (54.1%) of these patients do not have kidney function recorded in the EMR. This analysis highlights the need for improved clinical practices to ensure all patients are being safely monitored. - GFR > 60mL/min GFR < 60mL/min No GFR on record Diagnosed with heart failure Diagnosed with diabetes mellitus Prescribed ACEi/ARB Prescribed diuretic 4300 (39.0%) 762 (6.9%) 5956 (54.1%) 213 (1.9%) 8744 (79.4%) 7152 (64.9%) 3579 (32.5%)

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2024-10-01
DOI
https://doi.org/10.1681/asn.2024vas1vq07
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

SGLT2 Inhibitor Prescribing Practices in a Large Health System

Fitsum T. Hailemariam, Robert Kosalka
Journal of the American Society of Nephrology
Diabetes Treatment and Management
article

SGLT2 Inhibitor Prescribing Practices in a Large Health System

Fitsum T. Hailemariam, Robert Kosalka
article en

Abstract

Background: Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of medication that act on the renal proximal convoluted tubules to reduce the reabsorption of glucose. They were primarily used in diabetics to assist with glucose control and are now approved for the treatment of heart failure and chronic kidney disease (CKD). Once started on SGLT2 inhibitors, patients must be monitored for a decline in renal function especially if they are also put on angiotensin-converting enzyme inhibitors (ACEi), angiotensin receptor blockers (ARB), and/or diuretics, as they can lead to decreases in kidney function and dehydration/hypotension. Methods: This is a retrospective cohort study of patients who were prescribed SGLT2 inhibitors in the Jefferson Health System. Data was sourced from the electronic medical record (EMR) using a customized query that returned the most recent 3 glomerular filtration rate (GFR) measurements, diagnostic codes, prescribed ACEi or ARB therapy, and prescribed diuretics. Results: Eleven thousand and eighteen adults with SGLT2 inhibitors in their medication lists were analyzed. Of these, 5956 (54.1%) patients had no GFR on record, 8744 (79.4%) were diagnosed with diabetes, 7152 (64.9%) were on concurrent ACEi/ARB therapy and 3579 (32.5%) were on diuretics. Conclusion: SGLT2 inhibitors have become the standard of care in patients with diabetes, CKD, cardiovascular disease, and heart failure. However, the proportion of patients in our study with CKD and heart failure was lower than expected, 6.9% and 1.9%, respectively. The concurrent use of ACEi/ARB medications and diuretics can be safe provided there is adequate monitoring of the fluid status and renal function. A substantial proportion (54.1%) of these patients do not have kidney function recorded in the EMR. This analysis highlights the need for improved clinical practices to ensure all patients are being safely monitored. - GFR > 60mL/min GFR < 60mL/min No GFR on record Diagnosed with heart failure Diagnosed with diabetes mellitus Prescribed ACEi/ARB Prescribed diuretic 4300 (39.0%) 762 (6.9%) 5956 (54.1%) 213 (1.9%) 8744 (79.4%) 7152 (64.9%) 3579 (32.5%)

Journal of the American Society of NephrologyVol. 35(10S)
Thomas Jefferson University (US)
Openalex Percentile: Top 69%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

SGLT2 Inhibitor Prescribing Practices in a Large Health System — Fitsum T. Hailemariam, Robert Kosalka · Journal of the American Society of Nephrology (2024) | TGRS Research Map | TGRS